Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

26.30 +0.09 (+0.32%)
Streaming Delayed Price Updated: 11:37 AM EDT, Jun 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Have S&P 500 Index Funds, Often Touted as the Best Stock Investments, Become Dangerous? There's a Worrisome Development -- and a Possibly Better Alternative. ↗
The hard-earned dollars you park in a standard S&P 500 index fund may not be distributed the way you think they are. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take. ↗
Bristol Myers Squibb has a well-above-market yield of 4.5% and it appears reasonably safe. 
Via The Motley Fool
Topics Bonds Intellectual Property
News headline image
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About ↗
The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments. 
Via The Motley Fool
Thursday's session: most active stock in the S&P500 index ↗
Via Chartmill
News headline image
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion ↗
GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff. 
Via MarketBeat
Topics Intellectual Property
News headline image
Why Pfizer Stock Popped Today ↗
Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell. 
Via The Motley Fool
News headline image
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? ↗
One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up. 
Via The Motley Fool
News headline image
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase ↗
Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics... 
Via MarketBeat
News headline image
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears ↗
Caribou Biosciences (NASDAQ:CRBU) Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate... 
Via MarketBeat
News headline image
2 of Wall Street’s Favorite Stocks on Our Watchlist and 1 We Brush Off
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
Pfizer's Obesity Drug Shows 16% Weight Loss In Phase 2b Study ↗
Pfizer reports Phase 2b obesity drug data showing 15.9% weight loss as FDA expands HYMPAVZI use for hemophilia patients. 
Via Benzinga
Curious about the most active S&P500 stocks in today's session? ↗
Via Chartmill
News headline image
Hemostat Powder Market Size, Analysis Report By 2035 ↗
The most recent research report on the "Hemostat Powder Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts, an 
Via Talk Markets
Topics Economy
News headline image
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500? ↗
For a solid yield and strong upside potential, this pharmaceutical stock is worth considering. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
3 Dividend Stocks to Buy Hand Over Fist in June ↗
They sport recent dividend yields of 3.25%, 6.7%, and a whopping 7.7%. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer. ↗
The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems ↗
Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data ↗
Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where... 
Via MarketBeat
News headline image
2 Cash-Producing Stocks Worth Your Attention and 1 Facing Headwinds
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
News headline image
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052 ↗
Aclaris Therapeutics (NASDAQ:ACRS) executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting... 
Via MarketBeat
News headline image
Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer? ↗
Durability, not yield, is the deciding factor. 
Via The Motley Fool
News headline image
Avascular Necrosis Market Size, Industry Share By 2035 ↗
The most recent research report on the "Avascular Necrosis Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts, 
Via Talk Markets
Topics Economy
News headline image
3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
These stocks pay between 4.2% and 6.7% in dividends. 
Via The Motley Fool
News headline image
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? ↗
Whichever one you choose, you'll need patience before you can see solid returns. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026 ↗
It is finally bouncing back after several challenging years. 
Via The Motley Fool
News headline image
3 Large-Cap Stocks with Solid Fundamentals
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit... 
Via StockStory
News headline image
How to Recession-Proof Your Retirement Before the Second Half of 2026 ↗
You should consider these strategies if you can't afford to wait out another market crash. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
3 Dividend Stocks to Buy and Hold Forever ↗
These aren't the most exciting businesses, but they have a lot to offer to long-term investors. 
Via The Motley Fool
News headline image
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks ↗
Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.